MetrioPharm Press Releases
-
MetrioPharm Signs European Commission Grant Agreement for €7.9 Million
The project includes the conduct of a Phase II clinical trial with MetrioPharm’s lead compound MP1032 against COVID-19, as well as preclinical studies on the effect of MP1032 on mutant variants of SARS-CoV-2.
-
MetrioPharm Doses First Patient in Phase II Study of MP1032 in COVID-19
The study’s target is to determine if MP1032's anti-inflammatory effect can slow down the spread of the virus in recently hospitalized patients with moderate to severe coronavirus disease 2019, as well as alleviate COVID-19 symptoms.
-
MetrioPharm AG Strengthens Equity by CHF 27.5 M
MetrioPharm AG announces that two convertible loans granted by shareholders in the total amount of CHF 18.5 million have been converted to equity. The equity was increased by a further CHF 9 million through the exercise of subscription rights in two cash capital increases.
-
Thomas Christély joins management of MetrioPharm AG as CEO
Thomas Christély to start as CEO of MetrioPharm AG on October 1, 2021. Dr. Wolfgang Brysch will accelerate expansion of clinical development as CSO & CMO.
-
MetrioPharm Selected by European Commission for Funding as Part of the "HERA Incubator”
European Commission nominates MetrioPharm with Covid project "iMPact" to the list of HERA funded projects
-
MetrioPharm AG Obtains Patent Protection for its Lead Compound MP1032 in Brazil
MetrioPharm AG announces that a further substance patent has been obtained for its lead compound MP1032. The Brazilian patent BR 112012021857-3 was granted on June 22, 2021.
-
Long-term Toxicology Studies Confirm Very Good Safety Profile of MP1032
MetrioPharm AG reports positive results from two long-term preclinical toxicology studies in the rat and the dog.
-
MetrioPharm AG Announces Change In Management Team
MetrioPharm AG announces that Sven Zimmermann will leave the company as of March 31, 2021. Sven Zimmermann was the CFO of MetrioPharm AG since August 2019.
-
COVID-19 Therapeutic Agent: MetrioPharm Prepares to Conduct a Phase II Clinical Trial
Following positive data from pre-clinical studies published in the peer-reviewed International Journal of Molecular Science, the company believes that MP1032 has the potential to both, slow down the spread of the virus in the body, and alleviate COVID-19 symptoms.
-
MetrioPharm Announces Publication of Successful MP1032 Preclinical Data in COVID-19
MetrioPharm AG announces the publication of preclinical data showing its lead compound MP1032 could be a promising option for prevention and treatment of the SARS-CoV-2-induced cytokine storm.